Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.…
RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a Week
Aldeyra Therapeutics (NASDAQ: ALDX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 6 employees.
The shares were at 0.8400 USD on 20 November 2026, down 82.1% over 52 weeks. Its 52-week range is 0.5271 USD to 5.930 USD: the price is 85.8% below the high and 59.4% above the low.
Its market capitalisation is 50.70M USD.
Aldeyra Therapeutics reports return on equity of -76.5% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 40.52M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. The next earnings report is expected on 26 February 2027.